BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 3203969)

  • 21. Intranasal immunization with liposome-encapsulated plasmid DNA encoding influenza virus hemagglutinin elicits mucosal, cellular and humoral immune responses.
    Wang D; Christopher ME; Nagata LP; Zabielski MA; Li H; Wong JP; Samuel J
    J Clin Virol; 2004 Dec; 31 Suppl 1():S99-106. PubMed ID: 15567101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection.
    Hong SH; Byun YH; Nguyen CT; Kim SY; Seong BL; Park S; Woo GJ; Yoon Y; Koh JT; Fujihashi K; Rhee JH; Lee SE
    Vaccine; 2012 Jan; 30(2):466-74. PubMed ID: 22051136
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protollin: a novel adjuvant for intranasal vaccines.
    Jones T; Cyr S; Allard F; Bellerose N; Lowell GH; Burt DS
    Vaccine; 2004 Sep; 22(27-28):3691-7. PubMed ID: 15315848
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of poly[di(sodium carboxylatophenoxy)phosphazene] (PCPP) as mucosal adjuvant to induce protective immunity against respiratory pathogens.
    Shim DH; Ko HJ; Volker G; Potter AA; Mutwiri G; Babiuk LA; Kweon MN
    Vaccine; 2010 Mar; 28(11):2311-7. PubMed ID: 20060944
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alkyl polyglycoside, a highly promising adjuvant in intranasal split influenza vaccines.
    Wu H; Bao Y; Wang X; Zhou D; Wu W
    Hum Vaccin Immunother; 2017 Jun; 13(6):1-9. PubMed ID: 28129034
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intranasal inoculate of influenza virus vaccine against lethal virus challenge.
    Fan X; Su Q; Qiu F; Yi Y; Shen L; Jia Z; Liang P; Zou Y; Bi S
    Vaccine; 2018 Jul; 36(29):4354-4361. PubMed ID: 29880240
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral administration of cholera toxin-Sendai virus conjugate potentiates gut and respiratory immunity against Sendai virus.
    Liang XP; Lamm ME; Nedrud JG
    J Immunol; 1988 Sep; 141(5):1495-501. PubMed ID: 2842395
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection.
    Ichinohe T; Watanabe I; Ito S; Fujii H; Moriyama M; Tamura S; Takahashi H; Sawa H; Chiba J; Kurata T; Sata T; Hasegawa H
    J Virol; 2005 Mar; 79(5):2910-9. PubMed ID: 15709010
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit.
    Tamura S; Samegai Y; Kurata H; Nagamine T; Aizawa C; Kurata T
    Vaccine; 1988 Oct; 6(5):409-13. PubMed ID: 2848377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protective effect of nasal immunization of influenza virus hemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice.
    Isaka M; Zhao Y; Nobusawa E; Nakajima S; Nakajima K; Yasuda Y; Matsui H; Hasegawa T; Maeyama J; Morokuma K; Ohkuma K; Tochikubo K
    Microbiol Immunol; 2008 Feb; 52(2):55-63. PubMed ID: 18380802
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Secretory immunoglobulin A antibody response is conserved in aged mice following oral immunization with influenza virus vaccine.
    Chen KS; Quinnan GV
    J Gen Virol; 1989 Dec; 70 ( Pt 12)():3291-6. PubMed ID: 2607339
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sublingual immunization with a subunit influenza vaccine elicits comparable systemic immune response as intramuscular immunization, but also induces local IgA and TH17 responses.
    Gallorini S; Taccone M; Bonci A; Nardelli F; Casini D; Bonificio A; Kommareddy S; Bertholet S; O'Hagan DT; Baudner BC
    Vaccine; 2014 Apr; 32(20):2382-8. PubMed ID: 24434044
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influenza vaccine: development of a novel intranasal and subcutaneous recombinant adjuvant.
    Segura-Velázquez R; Cervantes J; Acosta E; Sánchez-Betancourt I; Villalobos N; Rodarte LF; Restelli M; Fragoso G; Sciutto E
    Vaccine; 2013 Aug; 31(37):4009-16. PubMed ID: 23746458
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single dose intranasal immunization with ISCOMATRIX vaccines to elicit antibody-mediated clearance of influenza virus requires delivery to the lower respiratory tract.
    Sanders MT; Deliyannis G; Pearse MJ; McNamara MK; Brown LE
    Vaccine; 2009 Apr; 27(18):2475-82. PubMed ID: 19368789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inactivated meningococci and pertussis bacteria are immunogenic and act as mucosal adjuvants for a nasal inactivated influenza virus vaccine.
    Berstad AK; Andersen SR; Dalseg R; Dromtorp S; Holst J; Namork E; Wedege E; Haneberg B
    Vaccine; 2000 Mar; 18(18):1910-9. PubMed ID: 10699340
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of immune response that protects mice from viral pneumonitis after a single intranasal immunization with influenza A virus and nanoemulsion.
    Myc A; Kukowska-Latallo JF; Bielinska AU; Cao P; Myc PP; Janczak K; Sturm TR; Grabinski MS; Landers JJ; Young KS; Chang J; Hamouda T; Olszewski MA; Baker JR
    Vaccine; 2003 Sep; 21(25-26):3801-14. PubMed ID: 12922114
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 38. H9N2 influenza whole inactivated virus combined with polyethyleneimine strongly enhances mucosal and systemic immunity after intranasal immunization in mice.
    Qin T; Yin Y; Huang L; Yu Q; Yang Q
    Clin Vaccine Immunol; 2015 Apr; 22(4):421-9. PubMed ID: 25673304
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity.
    Arulanandam BP; O'Toole M; Metzger DW
    J Infect Dis; 1999 Oct; 180(4):940-9. PubMed ID: 10479116
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant baculovirus vaccine containing multiple M2e and adjuvant LTB induces T cell dependent, cross-clade protection against H5N1 influenza virus in mice.
    Zhang J; Fan HY; Zhang Z; Zhang J; Zhang J; Huang JN; Ye Y; Liao M
    Vaccine; 2016 Jan; 34(5):622-629. PubMed ID: 26724200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.